Following the classical molecular mechanism of TET1-mediated transcriptional activation, we demonstrated that TET1 binds directly to the SFRP2 promoter, catalyzes 5-mC hydroxylation to 5-hmC in the promoter CpG islands, induces demethylation, initiates SFRP2 transcriptional activation, and ultimately inhibits EMT in pancreatic tumors. The gene discussed is SFRP2; the disease is pancreatic neoplasm.